VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+0.14%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$204M
AUM Growth
+$15.9M
(+8.5%)
Cap. Flow
+$16.5M
Cap. Flow
% of AUM
8.1%
Top 10 Holdings %
Top 10 Hldgs %
6.14%
Holding
488
New
66
Increased
245
Reduced
135
Closed
40
Top Buys
| 1 |
CrowdStrike
CRWD
|
$1.1M |
| 2 |
Netflix
NFLX
|
$1.03M |
| 3 |
Qualcomm
QCOM
|
$1.03M |
| 4 |
Royal Caribbean
RCL
|
$1M |
| 5 |
TJX Companies
TJX
|
$973K |
Top Sells
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
$1.11M |
| 2 |
Eli Lilly
LLY
|
$937K |
| 3 |
Freeport-McMoran
FCX
|
$933K |
| 4 |
Align Technology
ALGN
|
$933K |
| 5 |
Martin Marietta Materials
MLM
|
$930K |
Sector Composition
| 1 | Financials | 26.66% |
| 2 | Healthcare | 19.14% |
| 3 | Technology | 17.16% |
| 4 | Energy | 7.21% |
| 5 | Industrials | 6.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Companhia Siderúrgica Nacional
SID
$1.99B
| $128K | 0.06% |
55,610
+7,054
| +15% | +$16.2K |
|
|
LBPH
327
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $123K | 0.06% |
+4,538
| New | +$123K |
|
328
Nurix Therapeutics
NRIX
$758M
| $113K | 0.06% |
5,411
-4,282
| -44% | -$89.4K |
|
|
MORF
329
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $111K | 0.05% |
3,262
+327
| +11% | +$11.1K |
|
330
Disc Medicine
IRON
$2.11B
| $104K | 0.05% |
2,312
+824
| +55% | +$37.1K |
|
331
Erasca
ERAS
$457M
| $98K | 0.05% |
+41,526
| New | +$98K |
|
|
EXAI
332
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $97K | 0.05% |
19,018
+4,334
| +30% | +$22.1K |
|
333
Celcuity
CELC
$2.36B
| $96.7K | 0.05% |
+5,901
| New | +$96.7K |
|
334
Enliven Therapeutics
ELVN
$1.19B
| $96.1K | 0.05% |
+4,111
| New | +$96.1K |
|
335
Denali Therapeutics
DNLI
$2.26B
| $95K | 0.05% |
4,092
+357
| +10% | +$8.29K |
|
336
Dyne Therapeutics
DYN
$2.02B
| $94.8K | 0.05% |
2,687
-4,639
| -63% | -$164K |
|
|
AGEN
337
Agenus
AGEN
$138M
| $94.8K | 0.05% |
5,658
-33
| -0.6% | -$553 |
|
338
Biohaven
BHVN
$1.68B
| $94.1K | 0.05% |
2,710
+407
| +18% | +$14.1K |
|
339
Pharvaris
PHVS
$1.48B
| $94K | 0.05% |
+5,001
| New | +$94K |
|
340
AnaptysBio
ANAB
$613M
| $93.5K | 0.05% |
3,733
-818
| -18% | -$20.5K |
|
341
Praxis Precision Medicines
PRAX
$986M
| $93.5K | 0.05% |
+2,260
| New | +$93.5K |
|
342
MoonLake Immunotherapeutics
MLTX
$3.77B
| $93.2K | 0.05% |
2,120
+616
| +41% | +$27.1K |
|
343
Cytokinetics
CYTK
$6.34B
| $93K | 0.05% |
1,717
-650
| -27% | -$35.2K |
|
344
Merus
MRUS
$5.1B
| $92.9K | 0.05% |
1,570
-1,861
| -54% | -$110K |
|
345
Xenon Pharmaceuticals
XENE
$3.02B
| $92.8K | 0.05% |
2,380
+277
| +13% | +$10.8K |
|
346
Tango Therapeutics
TNGX
$772M
| $92.6K | 0.05% |
10,790
+2,288
| +27% | +$19.6K |
|
347
Avidity Biosciences
RNA
$6.48B
| $92.5K | 0.05% |
2,265
-8,524
| -79% | -$348K |
|
348
Vaxcyte
PCVX
$4.29B
| $92.3K | 0.05% |
1,223
-209
| -15% | -$15.8K |
|
349
Viking Therapeutics
VKTX
$3.03B
| $92.1K | 0.05% |
1,738
-2,773
| -61% | -$147K |
|
350
Celldex Therapeutics
CLDX
$1.52B
| $92K | 0.05% |
2,485
+86
| +4% | +$3.18K |
|